Correction: Mitochondrial DNA variation in Alzheimer’s disease reveals a unique microprotein called SHMOOSE (Molecular Psychiatry, (2023), 28, 4, (1813-1826), 10.1038/s41380-022-01769-3)

for the Alzheimer's Disease Neuroimaging Initiative

doi:10.1038/s41380-023-01956-w

Correction: Mitochondrial DNA variation in Alzheimer’s disease reveals a unique microprotein called SHMOOSE (Molecular Psychiatry, (2023), 28, 4, (1813-1826), 10.1038/s41380-022-01769-3)

for the Alzheimer's Disease Neuroimaging Initiative

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the by-line of this article, the following phrase was missing: Include the phrase “for the Alzheimer’s Disease Neuroimaging Initiative”. In the by-line of this article, the following author was missing: Regina Gonzalez Braniff. In the methods section of this article, the following text was missing: “Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD)”.

Original language	English (US)
Pages (from-to)	1827
Number of pages	1
Journal	Molecular Psychiatry
Volume	28
Issue number	4
DOIs	https://doi.org/10.1038/s41380-023-01956-w
State	Published - Apr 2023

ASJC Scopus subject areas

Psychiatry and Mental health
Cellular and Molecular Neuroscience
Molecular Biology

Access to Document

10.1038/s41380-023-01956-w

Cite this

Correction: Mitochondrial DNA variation in Alzheimer’s disease reveals a unique microprotein called SHMOOSE (Molecular Psychiatry, (2023), 28, 4, (1813-1826), 10.1038/s41380-022-01769-3). / for the Alzheimer's Disease Neuroimaging Initiative.
In: Molecular Psychiatry, Vol. 28, No. 4, 04.2023, p. 1827.

Research output: Contribution to journal › Comment/debate › peer-review

@article{e658290c550840db947b6cd5a22b7435,

title = "Correction: Mitochondrial DNA variation in Alzheimer{\textquoteright}s disease reveals a unique microprotein called SHMOOSE (Molecular Psychiatry, (2023), 28, 4, (1813-1826), 10.1038/s41380-022-01769-3)",

abstract = "In the by-line of this article, the following phrase was missing: Include the phrase “for the Alzheimer{\textquoteright}s Disease Neuroimaging Initiative”. In the by-line of this article, the following author was missing: Regina Gonzalez Braniff. In the methods section of this article, the following text was missing: “Data used in the preparation of this article were obtained from the Alzheimer{\textquoteright}s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer{\textquoteright}s disease (AD)”.",

author = "{for the Alzheimer's Disease Neuroimaging Initiative} and Brendan Miller and Kim, {Su Jeong} and Mehta, {Hemal H.} and Kevin Cao and Hiroshi Kumagai and Neehar Thumaty and Naphada Leelaprachakul and Braniff, {Regina Gonzalez} and Henry Jiao and Joan Vaughan and Jolene Diedrich and Alan Saghatelian and Arpawong, {Thalida E.} and Crimmins, {Eileen M.} and Nil{\"u}fer Ertekin-Taner and Tubi, {Meral A.} and Hare, {Evan T.} and Braskie, {Meredith N.} and L{\'e}a D{\'e}carie-Spain and Kanoski, {Scott E.} and Francine Grodstein and Bennett, {David A.} and Lu Zhao and Toga, {Arthur W.} and Junxiang Wan and Kelvin Yen and Pinchas Cohen",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature Limited 2023.",

year = "2023",

month = apr,

doi = "10.1038/s41380-023-01956-w",

language = "English (US)",

volume = "28",

pages = "1827",

journal = "Molecular Psychiatry",

issn = "1359-4184",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Correction

T2 - Mitochondrial DNA variation in Alzheimer’s disease reveals a unique microprotein called SHMOOSE (Molecular Psychiatry, (2023), 28, 4, (1813-1826), 10.1038/s41380-022-01769-3)

AU - for the Alzheimer's Disease Neuroimaging Initiative

AU - Miller, Brendan

AU - Kim, Su Jeong

AU - Mehta, Hemal H.

AU - Cao, Kevin

AU - Kumagai, Hiroshi

AU - Thumaty, Neehar

AU - Leelaprachakul, Naphada

AU - Braniff, Regina Gonzalez

AU - Jiao, Henry

AU - Vaughan, Joan

AU - Diedrich, Jolene

AU - Saghatelian, Alan

AU - Arpawong, Thalida E.

AU - Crimmins, Eileen M.

AU - Ertekin-Taner, Nilüfer

AU - Tubi, Meral A.

AU - Hare, Evan T.

AU - Braskie, Meredith N.

AU - Décarie-Spain, Léa

AU - Kanoski, Scott E.

AU - Grodstein, Francine

AU - Bennett, David A.

AU - Zhao, Lu

AU - Toga, Arthur W.

AU - Wan, Junxiang

AU - Yen, Kelvin

AU - Cohen, Pinchas

PY - 2023/4

Y1 - 2023/4

N2 - In the by-line of this article, the following phrase was missing: Include the phrase “for the Alzheimer’s Disease Neuroimaging Initiative”. In the by-line of this article, the following author was missing: Regina Gonzalez Braniff. In the methods section of this article, the following text was missing: “Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD)”.

AB - In the by-line of this article, the following phrase was missing: Include the phrase “for the Alzheimer’s Disease Neuroimaging Initiative”. In the by-line of this article, the following author was missing: Regina Gonzalez Braniff. In the methods section of this article, the following text was missing: “Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD)”.

UR - http://www.scopus.com/inward/record.url?scp=85146554555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146554555&partnerID=8YFLogxK

U2 - 10.1038/s41380-023-01956-w

DO - 10.1038/s41380-023-01956-w

M3 - Comment/debate

C2 - 36658336

AN - SCOPUS:85146554555

SN - 1359-4184

VL - 28

SP - 1827

JO - Molecular Psychiatry

JF - Molecular Psychiatry

IS - 4

ER -

Correction: Mitochondrial DNA variation in Alzheimer’s disease reveals a unique microprotein called SHMOOSE (Molecular Psychiatry, (2023), 28, 4, (1813-1826), 10.1038/s41380-022-01769-3)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this